Analysis News

In-depth stock market analysis, technical indicators, and investment commentary. Expert insights on market trends, valuations, and trading strategies.

Pharvaris Surges 17% as Phase 3 HAE Trial Meets Primary Endpoint
Analysis Daniel Marsh

Pharvaris Surges 17% as Phase 3 HAE Trial Meets Primary Endpoint

Pharvaris (PHVS) soared 17% after its oral HAE preventive met the primary endpoint in Phase 3, reducing monthly attacks by 83% versus placebo.

PHVS
Intel's High-NA Milestone: 1M Wafers, But Revenue Gap Looms
Analysis Daniel Marsh

Intel's High-NA Milestone: 1M Wafers, But Revenue Gap Looms

Intel's High-NA EUV milestone of 1 million wafers proves technical progress, but external foundry revenue is a mere $293M. The market watches for customer wins.

INTC ASML
Rivian's Software Upgrade: A Strategic Move That Doesn't Yet Solve Cash Flow Woes
Analysis Daniel Marsh

Rivian's Software Upgrade: A Strategic Move That Doesn't Yet Solve Cash Flow Woes

Rivian's RivianOS 2 update is a strategic step, but RIVN stock still faces an $849 million cash-flow test. The software must cut costs and boost subscriptions, not just improve the interface.

RIVN
Novartis Shares Plunge 9% as Key Drug Trial Misses Goal
Analysis Daniel Marsh

Novartis Shares Plunge 9% as Key Drug Trial Misses Goal

Novartis shares tumbled 9% after its lead Avidity drug failed a pivotal trial, erasing about $22 billion in value and raising doubts about its pipeline.

NVS
PG&E's $2B Capex Deferral: A Bid to Cut Debt That Could Cap Growth
Analysis Daniel Marsh

PG&E's $2B Capex Deferral: A Bid to Cut Debt That Could Cap Growth

PG&E defers $2B in 2027 capex to cut debt, trading at 7.9x forward earnings. The move lowers financial risk but slows growth, as wildfire policy remains unresolved.

PCG
Headlam's Frozen Equity: CVA Plan Leaves Shareholders in Limbo
Analysis Daniel Marsh

Headlam's Frozen Equity: CVA Plan Leaves Shareholders in Limbo

Headlam Group's shares stay suspended at 10.5p while administrators pursue a CVA and refinancing, but the plan offers no terms for existing shareholders, leaving equity value uncertain.

Renalytix Shares Rebound 36% on Recapitalization Plan
Analysis Daniel Marsh

Renalytix Shares Rebound 36% on Recapitalization Plan

Renalytix shares jumped 36% on AIM resumption after a £10.48M capital raise and debt conversion, but existing holders face 35% dilution.

RENX
Rolls-Royce's £20 Target: A $5.3B Cash Flow Hurdle
Analysis Daniel Marsh

Rolls-Royce's £20 Target: A $5.3B Cash Flow Hurdle

Rolls-Royce shares near 1,473p; a £20 target implies ~£5.3B annual free cash flow, 36% above 2026 guidance. Buybacks help, but operating performance is key.

RYCEY
Nintendo Shares Unchanged Ahead of Zelda Direct, Ocarina of Time Confirmed for Switch 2
Analysis Daniel Marsh

Nintendo Shares Unchanged Ahead of Zelda Direct, Ocarina of Time Confirmed for Switch 2

Nintendo shares closed unchanged at ¥8,750 despite confirming Ocarina of Time for Switch 2 in 2026. The market awaits the Zelda Direct for product details.

Panasonic's Two-Day Swing: Yen Strength Tests AI-Led Recovery Outlook
Analysis Daniel Marsh

Panasonic's Two-Day Swing: Yen Strength Tests AI-Led Recovery Outlook

Panasonic shares gave back Monday's rally in a two-day round trip, but the underlying AI-driven demand story remains intact despite yen headwinds.

IREN's AI Cloud: $4B ARR Target, Only 25% Live
Analysis Daniel Marsh

IREN's AI Cloud: $4B ARR Target, Only 25% Live

IREN's $4B AI cloud ARR is only 25% operational, leaving a wide gap between contracted and live capacity. The stock's valuation hinges on execution.

IREN
Avalon Technologies Slips After Record Rally; Nomura's Target Faces Scrutiny
Analysis Daniel Marsh

Avalon Technologies Slips After Record Rally; Nomura's Target Faces Scrutiny

Avalon Technologies shares eased 1.1% on Tuesday after a record-setting rally. Nomura's bullish target assumes robust JV returns, but key financial details remain undisclosed.